Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05255601
Registration number
NCT05255601
Ethics application status
Date submitted
15/02/2022
Date registered
24/02/2022
Date last updated
29/05/2025
Titles & IDs
Public title
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Query!
Scientific title
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Query!
Secondary ID [1]
0
0
2023-503715-14
Query!
Secondary ID [2]
0
0
CA224-069
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RELATIVITY-069
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lymphoma, Non-Hodgkin
0
0
Query!
Hodgkin Disease
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Hodgkin's
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Relatlimab
Treatment: Drugs - Nivolumab
Experimental: Relatlimab + Nivolumab -
Treatment: Drugs: Relatlimab
Specified Dose on Specified Days
Treatment: Drugs: Nivolumab
Specified Dose on Specified Days
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of dose-limiting toxicities (DLTs)
Query!
Assessment method [1]
0
0
DLT evaluation window is 4 weeks from start of treatment. Safety evaluation will continue up to 135 days following last dose.
Query!
Timepoint [1]
0
0
Up to 135 days following last dose
Query!
Primary outcome [2]
0
0
Maximum tolerated dose or Recommended phase 2 dose (MTD/RP2D)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 135 days following last dose
Query!
Primary outcome [3]
0
0
Number of participants with Adverse Events (AEs)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 135 days following last dose
Query!
Primary outcome [4]
0
0
Number of participants with serious adverse events (SAEs)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Up to 135 days following last dose
Query!
Primary outcome [5]
0
0
Number of participants with AEs leading to discontinuation
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Up to 135 days following last dose
Query!
Primary outcome [6]
0
0
Number of deaths
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Up to 2 years from the last treatment of last participant
Query!
Primary outcome [7]
0
0
Number of participants with clinical laboratory abnormalities
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Up to 135 days following last dose
Query!
Primary outcome [8]
0
0
Maximum observed plasma concentration (Cmax)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Up to 96 weeks
Query!
Primary outcome [9]
0
0
Trough observed concentration (Ctrough)
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Up to 96 weeks
Query!
Primary outcome [10]
0
0
Time of maximum observed plasma concentration (Tmax)
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Up to 96 weeks
Query!
Primary outcome [11]
0
0
Area Under the Curve within a dosing interval (AUC(TAU))
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Up to 96 weeks
Query!
Primary outcome [12]
0
0
Complete Metabolic Response (CMR) Rate defined as the proportion of all response-evaluable participants who achieve the best response of CMR using Lugano 2014 criteria
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Up to 2 years from the last treatment of last participant
Query!
Secondary outcome [1]
0
0
Number of participants with AEs
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 135 days following last dose
Query!
Secondary outcome [2]
0
0
Number of participants with SAEs
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 135 days following last dose
Query!
Secondary outcome [3]
0
0
Number of participants with AEs leading to discontinuation
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 135 days following last dose
Query!
Secondary outcome [4]
0
0
Number of deaths
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Up to 2 years from the last treatment of last participant
Query!
Secondary outcome [5]
0
0
Number of participants with clinical laboratory abnormalities
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Up to 135 days following last dose
Query!
Secondary outcome [6]
0
0
Overall Response Rate (ORR) defined as the proportion of all response- evaluable participants who achieve a best response of CMR or partial metabolic response (PMR) using the Lugano 2014 classification
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Up to 2 years from the last treatment of last participant
Query!
Eligibility
Key inclusion criteria
* Participants with pathologically confirmed high-risk R/R cHL, after non-response to or failure of 1or more lines of standard therapy.
* Participants with pathologically confirmed R/R NHL after non-response to or failure of 1or more lines of standard therapy, including, but not limited to, R/R primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL).
* Participants with pathologically confirmed R/R NHL after non-response to or failure of 2 or more lines of standard therapy, including Burkitt lymphoma (blast count <25% malignant Burkitt cells and/or per the investigator's clinical assessment of risk status), lymphoblastic lymphoma (blast count < 25% of marrow nucleated cells and/or per the investigator's clinical assessment of risk status), NK/T-cell lymphoma (nasal and non-nasal NK/T-cell lymphoma subtypes, but not aggressive NK/T-cell leukemia/lymphoma subtype).
* The participant's current disease state must be R/R to standard therapy.
* Participants must have measurable PET positive disease in both cHL and NHL cohorts.
Query!
Minimum age
No limit
Query!
Query!
Maximum age
30
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with leptomeningeal seeding.
* Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies.
* Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents.
* Participants with clinically significant systemic illnesses unrelated to the cancer as judged by the investigators, which would compromise the participant's ability to tolerate the study treatment.
* Participants with autoimmune disease.
* Prior allogeneic bone marrow transplantation.
Other protocol-defined inclusion/exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/09/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
5/07/2028
Query!
Actual
Query!
Sample size
Target
68
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Query!
Recruitment hospital [1]
0
0
University of New South Wales UNSW - Sydney Childrens Hospital SCH - The Centre for Cancer and Blood Disorders - Randwick
Query!
Recruitment hospital [2]
0
0
Royal Childrens Hospital RCH - Queensland Childrens Hospital - South Brisbane
Query!
Recruitment hospital [3]
0
0
Perth Childrens Hospital - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [3]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Delaware
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Minnesota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Mississippi
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Jersey
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Virginia
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Wisconsin
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Angers Cedex 9
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Bordeaux
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Caen
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
La Tronche
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Lyon
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Marseille
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Montpellier
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Paris
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Rennes
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Strasbourg
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Aachen
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Berlin
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Giessen
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Hamburg
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Muenster
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Munich
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Aviano
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Bologna
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Florence
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Genoa
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Milano
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Milan
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Monza
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Napoli
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Padova
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Pavia
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Roma
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Turin
Query!
Country [46]
0
0
Netherlands
Query!
State/province [46]
0
0
Utrecht
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Barcelona
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Navarra
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Madrid
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
Santander
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Sevilla
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Valencia
Query!
Country [53]
0
0
United Kingdom
Query!
State/province [53]
0
0
Cambridgeshire
Query!
Country [54]
0
0
United Kingdom
Query!
State/province [54]
0
0
England
Query!
Country [55]
0
0
United Kingdom
Query!
State/province [55]
0
0
Londonderry
Query!
Country [56]
0
0
United Kingdom
Query!
State/province [56]
0
0
Nottinghamshire
Query!
Country [57]
0
0
United Kingdom
Query!
State/province [57]
0
0
Somerset
Query!
Country [58]
0
0
United Kingdom
Query!
State/province [58]
0
0
Tyne And Wear
Query!
Country [59]
0
0
United Kingdom
Query!
State/province [59]
0
0
West Midlands
Query!
Country [60]
0
0
United Kingdom
Query!
State/province [60]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05255601
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
BMS Study Connect Contact Center www.BMSStudyConnect.com
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
855-907-3286
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05255601
Download to PDF